Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Eur Cytokine Netw
; 31(3): 81-93, 2020 Sep 01.
Article
in English
| MEDLINE | ID: covidwho-999892
ABSTRACT
Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-6
/
Tumor Necrosis Factor-alpha
/
Pandemics
/
Cytokine Release Syndrome
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Antibodies
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur Cytokine Netw
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
Ecn.2020.0451
Similar
MEDLINE
...
LILACS
LIS